Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for CI Medical Co's Debt-to-EBITDA or its related term are showing as below:
TSE:3540'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.57 Med: 2.24 Max: 4.07
Current: 0.57
During the past 10 years, the highest Debt-to-EBITDA Ratio of CI Medical Co was 4.07. The lowest was 0.57. And the median was 2.24.
TSE:3540's Debt-to-EBITDA is not ranked
in the Consumer Packaged Goods industry.
Industry Median: 2.105
vs TSE:3540: 0.57
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
CI Medical Co Debt-to-EBITDA Related Terms
CI Medical Co Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for CI Medical Co's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3540 vs PG, CL, KMB: Debt-to-EBITDA Comparison
For the Household & Personal Products subindustry, CI Medical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CI Medical Co Debt-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, CI Medical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where CI Medical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Jun. 2025) EBITDA data.
CI Medical Co (TSE:3540) has a Debt-to-EBITDA of 0.75 as of Jun. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CI Medical Co. This is 67% below median its historical median of 2.24. Over the past decade, CI Medical Co's Debt-to-EBITDA has ranged from 0.57 to 4.07.
Is CI Medical Co's Debt-to-EBITDA too high?
CI Medical Co's current Debt-to-EBITDA of 0.75 is 67% below median its 10-year median of 2.24. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 4.07. The Consumer Packaged Goods industry median Debt-to-EBITDA is 2.11. CI Medical Co's value of 0.75 is 64.4% below this industry median. Overall, CI Medical Co has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does CI Medical Co's Debt-to-EBITDA compare to PG and CL?
CI Medical Co's Debt-to-EBITDA of 0.75 can be compared against companies in the Consumer Packaged Goods industry. The industry median Debt-to-EBITDA is 2.11. CI Medical Co's value of 0.75 is 64.4% below this benchmark. Historically, CI Medical Co's own Debt-to-EBITDA has ranged from 0.57 to 4.07 over the past decade. While the company's 10-year median is 2.24 vs. the industry median of 2.11, CI Medical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Consumer Packaged Goods company?
The median Debt-to-EBITDA among Consumer Packaged Goods companies is 2.11, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CI Medical Co's current Debt-to-EBITDA of 0.75 is 64.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on CI Medical Co. For the Consumer Packaged Goods industry, the median Debt-to-EBITDA is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CI Medical Co's current Debt-to-EBITDA is 0.75, which is 67% below median its own 10-year median of 2.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CI Medical Co stock overvalued right now?
CI Medical Co (TSE:3540) has a current Debt-to-EBITDA of 0.75. The stock's GF Value™ is 円2,121.23, compared to a current price of 円1,492.00 — trading 29.7% below its estimated fair value. The current Debt-to-EBITDA is 0.75, which is 67% below median its 10-year median of 2.24 and 64.4% below the Consumer Packaged Goods industry median of 2.11. CI Medical Co's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For CI Medical Co (TSE:3540), the current Debt-to-EBITDA is 0.75 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CI Medical Co (TSE:3540) Overvalued in 2026?
Based on GuruFocus' analysis, CI Medical Co stock appears to be undervalued.
The current stock price of 円1,492.00 is trading 29.7% below its estimated GF Value™ of 円2,121.23.
Key valuation signals for TSE:3540:
Debt-to-EBITDA: 0.75 (67% below median its 10-year median of 2.24)
GF Value™: 円2,121.23 vs. price of 円1,492.00 (29.7% below fair value)
Industry Position: 64.4% below the Consumer Packaged Goods median
No single metric tells the full story. See the TSE:3540 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CI Medical Co Ltd engages in the development, manufacturing, and sales of dental care products. It operates 3D design labs; it offers advertising and marketing services through its website "Dental Mall" and also manages oral health care website "Ci Mall" and "Dental Fit" through which it sells oral health products and dentures. It serves medical cooperatives, dental clinics, dental associations, health centers, dental colleges, veterinary clinics, nursing home care facilities, and dental dealers.
70GF Score
Get the complete analysis for TSE:3540
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3540 has been successfully added to your 
